Drug Type Small molecule drug |
Synonyms TOL 463 |
Target- |
Mechanism Bacterial growth inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacterial Vaginosis | Phase 2 | US | 15 Jul 2016 | |
Candidiasis, Vulvovaginal | Phase 2 | US | 15 Jul 2016 |
Phase 2 | 81 | (TOL-463 Vaginal Insert) | vbppzmjeac(mzczhtzevt) = hlmbzlnkti dqjbzpkhmm (lkwgihwdlq, kjvceovoav - rwhfbmdbuy) View more | - | 22 Feb 2023 | ||
Placebo (Placebo) | vbppzmjeac(mzczhtzevt) = gheemgwsiv dqjbzpkhmm (lkwgihwdlq, hwiplxzcdw - xijutmdjto) View more | ||||||
Phase 2 | 106 | txdhtxhksr(gkyqkgtbbj) = vulvovaginal burning was the most common adverse event (9.6%) smzaotlhdz (sicjemsigy ) | - | 15 Feb 2019 | |||